MedTrace Logo

Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

NCT02317484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 231

Last updated 2018-04-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate clinical efficacy and safety of Sodium Glucose Co-transporter 2 (SGLT2) inhibitor, ipragliflozin, at doses of 50mg and 100mg, for Type II Diabetes under usual care. It is also to investigate and analyze the exploratory influential factor of ipragliflozin treatment on clinical efficacy and safety.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Ipragliflozin (SGLT2 inhibitor)

Sponsors & Collaborators

  • Osaka Saiseikai Nakatsu Hospital

    collaborator OTHER

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

    lead OTHER

Principal Investigators

  • Haruo Nishimura · Osaka Saiseikai Nakatsu Hospital

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-11-21
Completion
2018-02-28

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02317484 on ClinicalTrials.gov